Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 21Active not recruiting 5Withdrawn 2Suspended 2Not yet recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Prostatic Neoplasms 4Pancreatic Neoplasms 4Melanoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma 2Glioblastoma 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Xeroderma Pigmentosum 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Papillomavirus Infections 1Neuroblastoma 1

Interventions

Cyclophosphamide 8Azacitidine 8fludarabine phosphate 6fludarabine 6Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Methotrexate 5Cyclosporine 5Busulfan 5Decitabine 4Tacrolimus 3Mycophenolic Acid 3Filgrastim 3Cytarabine 3AP 1903 reagent 3venetoclax 2magrolimab 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Saline Solution 2Radiotherapy 2Nivolumab 2Cyclosporins 2Biopsy 2Alemtuzumab 2tumor-cells apoptosis factor, human 1sabatolimab 1ponatinib 1plerixafor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Myelodysplastic Syndromes × Specimen Handling × Clear all
NCT06572631 2025-05-25

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

City of Hope Medical Center

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

City of Hope Medical Center

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡